News
News
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides – NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
SHELTON, CONNECTICUT - July 6, 2023 - NanoViricides, Inc. (NYSE American: NNVC) reports that the clinical trial of its broad-spectrum...
Read moreDetails
DSS, Inc. Announces Record and Distribution Date for Impact Biomedical Spin-Off Special Dividend
ROCHESTER, N.Y., June 26, 2023 (GLOBE NEWSWIRE) DSS, Inc. (NYSE American: DSS), a multinational company operating nine business divisions through...
Read moreDetails
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...
Read moreDetails
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...
Read moreDetails
Charge Enterprises Reports Record Infrastructure Backlog Surpassing $100 Million and Reaffirms Growth Strategy
Charge Enterprises, Inc. (Nasdaq: CRGE) today reported record backlog after the close of the first quarter 2023 and reaffirmed its...
Read moreDetailsCharge Enterprises Sets Date for 2023 First Quarter Financial Results Webcast
Charge Enterprises, Inc. (Nasdaq: CRGE) plans to host a public results webcast on May 10, 2023, during which Charge’s executive...
Read moreDetails
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
NanoViricides, Inc. (NYSE Amer.: NNVC) a global leader in nanomedicines against viruses, announced today that it has executed a License...
Read moreDetails
SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including...
Read moreDetails
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today...
Read moreDetails
Amesite and NAFEO Alliance Announce Expansion to Twelve Member Universities
Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets,...
Read moreDetails